EUVIMEDEUVIMED entdecken
Open Access

Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade

Matthew E Growdon, Natalie Tjota, Rachel Campbell, Phyllis Gayda, Bocheng Jing, W James Deardorff, Lisa M McCarthy, Kenneth S Boockvar, Michael A Steinman

JAMA Network Open · 02.12.2025 · 8 (12) · e2545274

DOI: 10.1001/jamanetworkopen.2025.45274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 02.12.2025. Verfasst von Matthew E Growdon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Geriatrics, University of California, San Francisco. Hauptthemen laut MEDLINE: Gabapentin, Clinical Decision-Making, Pregabalin, Practice Patterns, Physicians'. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Prescribing cascades are an underrecognized driver of polypharmacy among older adults (aged ≥65 years). The clinical decision-making processes underlying cascades and their downstream consequences are poorly understood.

Objective

To explore clinical reasoning leading to prescribing cascades and downstream outcomes (eg, falls, electrolyte abnormalities) via the exemplar gabapentinoid (gabapentin and pregabalin)–loop diuretic (LD) cascade. Design, Setting, and Participants This cohort study randomly selected medical records from a cohort of US veterans aged 66 years or older between January 1, 2013, and August 31, 2019, who potentially experienced the gabapentinoid-LD prescribing cascade. The medical record review and data analysis were performed between October 24, 2023, and July 22, 2025. Exposures Initiation of gabapentinoid and LD. Main Outcomes and Measures Abstractors evaluated clinical documentation in the 30 days prior to and 60 days after LD initiation to evaluate decision-making processes and potential downstream outcomes of the gabapentinoid-LD cascade. Secondary analyses examined whether a dementia diagnosis was associated with clinician decision-making and patient outcomes.

Results

The analytic cohort comprised 120 patients (mean [SD] age, 73.9 [7.1] years; 116 male [96.7%]; 106 [88.3%] taking ≥5 long-term medications). Documentation of a differential diagnosis for edema was noted in 73 patients (60.8%), most commonly referencing congestive heart failure (n = 47 [39.2%]) and/or venous stasis (n = 16 [13.3%]). Gabapentinoids were rarely noted in the differential (n = 4 [3.3%]). The majority of clinicians documented the indication for LD (n = 116 [96.7%]), most commonly for lower-extremity edema (n = 104 [86.7%]), congestive heart failure (n = 16 [13.3%]), and/or dyspnea (n = 15 [12.5%]). In the 60 days following LD initiation, 28 patients (23.3%) experienced 37 events potentially attributable to LD initiation. The most common downstream events were worsening kidney function (n = 9 [7.5%]), orthostasis (n = 7 [5.8%]), electrolyte abnormalities (n = 6 [5.0%]), and falls (n = 5 [4.2%]). Six patients (5.0%) were evaluated in the emergency department and/or hospital for potential downstream events. Documentation of differential diagnoses, indications, actions taken regarding gabapentinoids, and downstream events generally did not vary between patients with and without dementia. Conclusions and Relevance This cohort study found that among older veterans who received LD following gabapentinoid initiation and experienced a potential gabapentinoid-LD prescribing cascade, clinicians almost never explicitly considered gabapentinoid adverse drug effects in their treatment of edema. These findings suggest that potential downstream harms of this overlooked prescribing cascade are common, underscoring the importance of addressing prescribing cascades in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GabapentinClinical Decision-MakingPregabalinPractice Patterns, Physicians'Sodium Potassium Chloride Symporter InhibitorsHumansAgedMaleFemaleAged, 80 and overCohort StudiesPolypharmacyUnited StatesVeterans

Substanzen

GabapentinPregabalinSodium Potassium Chloride Symporter Inhibitors

Autor:innen und Institutionen

  • Division of Geriatrics, University of California, San Francisco.
  • San Francisco Veterans Affairs Medical Center, San Francisco, California.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
  • Institute for Better Health, Trillium Health Partners, Mississauga, Ontario, Canada.
  • Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham.
  • Geriatrics Research, Education, and Clinical Center, Birmingham VA Health Care System, Birmingham, Alabama.

Förderung

  • NIA NIH HHS

Zitieren

APA

Growdon, M. E., Tjota, N., Campbell, R., Gayda, P., Jing, B., Deardorff, W. J., McCarthy, L. M., Boockvar, K. S., & Steinman, M. A. (2025). Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade. JAMA Network Open, 8(12), e2545274. https://doi.org/10.1001/jamanetworkopen.2025.45274

Vancouver

Growdon ME, Tjota N, Campbell R, Gayda P, Jing B, Deardorff WJ, et al. Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade. JAMA Network Open. 2025;8(12):e2545274. doi:10.1001/jamanetworkopen.2025.45274

BibTeX
@article{Growdon2025,
  author = {Growdon, Matthew E and Tjota, Natalie and Campbell, Rachel and Gayda, Phyllis and Jing, Bocheng and Deardorff, W James and McCarthy, Lisa M and Boockvar, Kenneth S and Steinman, Michael A},
  title = {Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {12},
  pages = {e2545274},
  doi = {10.1001/jamanetworkopen.2025.45274}
}
Kostenlos starten →